This FAQ discusses the PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever study of hemodynamically supported high-risk PCI patients.
Mitul Patel, M.D., Alexander Truesdell, M.D. and Katherine Kunkel, M.D., discuss the implications of the DanGer Shock RCT for community and academic centers.
Jena Billig discusses heparin-free purge solution and the features of the second-generation Impella 5.5® with SmartAssist® in this critical care transport webinar.
The significance of the DanGer Shock trial lies in its milestone findings for cardiology, potentially reshaping patient care by establishing routine Impella use as a life-saving intervention for STEMI patients with shock.
This overview article provides a framework for this series of articles. It addresses European recommendations and best practices for patient management and mechanical circulatory support (MCS) during high risk intervention, highlighting the following topics...
This article examines current evidence for the use of mechanical circulatory support (MCS) in cardiogenic shock and discusses how the scientific community can advance research in this area.
NPS-1674
This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].
The Protected PCI community
is now on HeartRecovery.com
Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
